金城医药 (300233)
Shandong Jincheng Pharmaceutical Group Co.,Ltd.
K-Line Chart
No K-line data available
Company NameShandong Jincheng Pharmaceutical Group Co., Ltd.
Listing Date2011-06-22
Issue Price18.6RMB
Registered Capital38387.458710k RMB
Legal RepresentativeZhao Yeqing
Registered AddressNo. 1 Shuangshan Road, Zichuan Economic Development Zone, Zibo City, Shandong Province
IndustryChemical Pharmaceuticals
Main BusinessResearch, development, production, and sales of cephalosporin antibiotic pharmaceutical intermediates.
Company ProfileShandong Jincheng Pharmaceutical Group Co., Ltd. is a national high-tech enterprise and a listed company on the ChiNext board. Through the dual-drive development model of "Industry + Capital", it has built a unique pharmaceutical and health industrial chain with Jincheng characteristics. Its business scope covers biopharmaceuticals, cephalosporin pharmaceutical intermediates, specialty APIs, finished dosage forms, health products, new materials, and other industrial fields. It has now formed an industrial scale with annual operating revenue exceeding RMB 2 billion and total assets nearing RMB 5 billion.
Stock Details
1. Key Indicators
- Total Shares(W): 38387.46
- Circulating A-Shares(W): 37170.43
- Earnings Per Share(RMB): 0.0800
- Net Assets Per Share(RMB): 9.5089
- Operating Revenue(W RMB): 193202.56
- Total Profit(W RMB): 5057.78
- Net Profit Attributable to Parent(W RMB): 3157.71
- Net Profit Growth Rate(%): -79.10
- Weighted Return on Equity(%): 0.8500
- Operating Cash Flow Per Share(RMB): 0.4800
- Undistributed Profit Per Share(RMB): 2.0441
- Capital Reserve Per Share(RMB): 6.0637
2. Main Business
The main business covers:
- Pharmaceutical Intermediates
- Active Pharmaceutical Ingredients (APIs)
- Finished Dosage Forms
3. Company Basic Information
- Company Name: Shandong Jincheng Pharmaceutical Group Co., Ltd.
- Listing Date: 2011-06-22
- Industry: Pharmaceutical Manufacturing
- Address: No.1 Shuangshan Road, Zichuan Economic Development Zone, Zibo City, Shandong Province, China
- Website: www.jinchengpharm.com
- Company Profile：The Company was established by Shandong Jincheng Pharmaceutical Chemical Co., Ltd. through a corporate restructuring. Based on the audited net assets of RMB 162,018,936.53 as of December 31, 2007, it was converted into 90 million shares at a ratio of 1:0.5555. The Company obtained its business license from the Zibo Administration for Industry and Commerce on February 28, 2008, with registration number 370300018517205.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Zibo Jincheng Industrial Investment Co., Ltd. | Corporate Legal Person | 7855.22 | 21.13 |
| 2 | National Social Security Fund 502 Portfolio | Social Security Fund | 854.84 | 2.30 |
| 3 | Fullgoal Precision Healthcare Flexible Allocation Hybrid Securities Investment Fund A | Fund | 496.10 | 1.33 |
| 4 | Qingdao Fuhe Investment Co., Ltd. | Corporate Legal Person | 477.00 | 1.28 |
| 5 | Basic Pension Insurance Fund 2108 Portfolio | Social Security Fund | 378.28 | 1.02 |
| 6 | National Social Security Fund 601 Portfolio | Social Security Fund | 334.29 | 0.90 |
| 7 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 333.61 | 0.90 |
| 8 | Invesco Great Wall Light Asset Investment Hybrid Securities Investment Fund (LOF) | Fund | 300.00 | 0.81 |
| 9 | Guotai Jiatai Stock Special Pension Product - China Merchants Bank Co., Ltd. | Asset Management Plan | 271.77 | 0.73 |
| 10 | E Fund Ke Rui Flexible Allocation Hybrid Securities Investment Fund | Fund | 197.16 | 0.53 |
5. Concept Sectors
- Biological Vaccine
- Graphene
- Vitamins
- Medical Aesthetics Concept
- Tobacco Concept
- New Tobacco
- Assisted Reproduction
- Hepatitis Concept
- Innovative Drugs
- Synthetic Biology
- AI Healthcare
- Margin Trading & Securities Lending
- Low-Profit Stock
- New Social Security Fund Holdings
- Fund Increased Holdings
- Specialized, Sophisticated, Distinctive, and Innovative SMEs
- Institutional Accumulation
Remarks
- Data update date: 2026-01-01
- Data source: Public Market Information